Clinical trial
First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia
NCT00322452 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00322452 |
|---|---|
| Title | First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia |
| Official title | Open Label, Randomised, Parallel Group, Multicentre, Ph III Study To Assess Efficacy, Safety & Tolerability Of Gefitinib (IRESSA™) Versus Carboplatin/Paclitaxel DC As 1st-Line Treatment In Selected Patients With Stage IIIB / IV NSCLC In Asia |
| Acronym | IPASS |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Gefitinib, Carboplatin, Paclitaxel |
| Enrollment | 1,329 |
| Start date | Mar 1, 2006 |
| Primary completion | Apr 1, 2008 |
| Completion | Jun 1, 2010 |
| First posted | May 8, 2006 |
| Last update posted | Nov 7, 2013 |
| Countries | China, Hong Kong, Indonesia, Japan, Malaysia, Philippines, Singapore, Taiwan, Thailand |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: